IFN-β is a widely prescribed treatment for multiple sclerosis (MS)3, yet, it consistently worsens disease in patients with neuromyelitis optica spectrum disorder (NMOSD)4,5. The gene discussed is IFNB1; the disease is myeloid sarcoma.